Attorney Docket No.: PB60557USw

ABSTRACT

Compounds of formula (I):

$$Ar^{1} - CHCH_{2}NHCR^{4}R^{5}(CH_{2})_{k} - (CH_{2})_{n}O(CH_{2})_{m}Z-(CH_{2})_{p}(CR^{8}R^{b})_{t} - (CH_{2})_{m}Z-(CH_{2})_{p}(CR^{8}R^{b})_{t} - (CH_{2})_{m}Z-(CH_{2})_{p}(CR^{8}R^{b})_{t} - (CH_{2})_{m}Z-(CH_{2})_{p}(CR^{8}R^{b})_{t} - (CH_{2})_{m}Z-(CH_{2})_{p}(CR^{8}R^{b})_{t} - (CH_{2})_{m}Z-(CH_{2})_{p}(CR^{8}R^{b})_{t} - (CH_{2})_{m}Z-(CH_{2})_{p}(CR^{8}R^{b})_{t} - (CH_{2})_{m}Z-(CH_{2})_{$$

and salts, solvates, and physiologically functional derivatives thereof, useful for the prophylaxis or treatment of a clinical condition for which a selective β_2 -adrenoreceptor agonist is indicated, for example asthma or chronic obstructive pulmonary disease (COPD).